Tempus AI TEM is transitioning from a heavy-investment growth stage toward improved operating leverage and a more scalable ...

Piper Sandler 37th Annual Healthcare Conference December 3, 2025 10:30 AM ESTCompany ParticipantsJames Rogers - Chief ...

Tempus AI (NASDAQ:TEM) isn't an AI stock that immediately comes to mind when one thinks of machine-learning-driven technological innovators with disruptive potential. Undoubtedly, the AI revolution ...

Tempus AI stands out as a leader in healthcare AI, showing strong execution and robust Q3 results despite recent stock volatility. TEM reported 85% revenue growth, expanding gross margins, and solid ...

In the first nine months of 2025, Tempus AI Inc. TEM achieved several key regulatory milestones that strengthened its position in AI-driven diagnostics. In September 2025, the company received FDA 510 ...

Tempus AI carries an average analyst price target of $61.40, with a tight range between $48 and $74, indicating strong consensus around near-term execution potential. Analysts highlight Tempus’ ...

Two Ark Invest ETFs added Tempus AI stock to their holdings last Friday. A BTIG analyst sees significant upside to Tempus AI stock. Growth investors shouldn't dismiss Tempus AI stock solely based on ...

Turbine and AstraZeneca have entered a partnership to enhance the discovery of antibody-drug conjugates (ADCs) using the former’s virtual disease models. The partnership will leverage Turbine’s ...

The smart money has taken a liking to Tempus AI (TEM). Though the mid-cap is choppy, the growth profile and recent margin gains are hard to ignore as applied AI looks to pick up more traction. Tempus ...

A well-known analyst believes this AI healthcare stock has room to soar. According to data provided by S&P Global Market Intelligence, Tempus AI stock rose 10.9% from the end of last Friday's market ...